P
revious reports indicate that in ␣ 1 -antitrypsin (AAT) deficiency symptoms and signs of asthma occur with emphysema. [1] [2] [3] [4] The diagnosis of asthma is difficult because the major characteristics of asthma, episodic wheezing and reversible airway obstruction, are common in populations with a diag-nosis of COPD. 5, 6 These clinical features may be related to anatomy of the small airways and loss of elastic recoil rather than those immune-mediated inflammatory processes commonly found in patients with asthma. 7 Although smoking is the most important risk factor for development of early emphysema in those with severe AAT deficiency, it may not be the only factor contributing to the development of airflow obstruction. For example, the National Heart, Lung, and Blood Institute (NHLBI)-sponsored AAT registry reported that a bronchodilator response is one factor that is associated with a more rapid decline in FEV 1 . 8 The impact of asthma on the course of irreversible airflow obstruction in those with severe AAT deficiency is poorly understood. Lack of an effective airway antiprotease screen may increase the propensity to inflammation, which may lead to airway remodeling and an accelerated FEV 1 decline. It was therefore determined if a greater FEV 1 decline occurred in registry participants showing the clinical features of asthma compared to those without.
If such a decline is in part caused by the lack of an effective antiprotease screen in the lower airways, increasing the airway concentration of AAT by augmentation therapy might ameliorate inflammation, reduce airway responsiveness, and preserve airway integrity. Therefore, we also examined whether augmentation therapy with AAT reduced the rate of FEV 1 decline in the group with features of asthma.
Materials and Methods
The organizational structure of the NHLBI-sponsored registry has been described previously. 9 The study was designed to prospectively study, over 5 years, the natural history of a cohort of subjects with AAT deficiency. The total number of participants enrolled was 1,129. All participants were Ն 18 years old, provided informed consent, and had a serum AAT level Ͻ 11 mol/L (or genotypic PI * ZZ by DNA probe analysis) as determined by a central laboratory. At each visit, spirometry measurements were obtained before and after bronchodilator according to American Thoracic Society criteria. Highly reproducible measurements were achieved. 10 A single IgE determination was made on stored serum collected during the first visit using antigenic nephelometry (Behring Diagnostics; Westwood, MA) and a commercial standard (Behring Diagnostics).
All participants completed the American Thoracic SocietyDivision of Lung Disease 1978 questionnaire 9 on the initial visit, and modified forms were completed on subsequent visits. The responses to question 13 (Does your chest ever sound wheezy or whistling?) and question 14 (Have you ever had an attack of wheezing that has made you feel short of breath?) and responses to questions of previous doctor-diagnosed asthma and respiratory allergies were analyzed. Participants were defined as having asthmatic features if they had the following: (1) demonstrated a Ն 12% improvement in FEV 1 of at least 200 mL after bronchodilator on any visit, (2) had a history of more than one attack of wheezing with shortness of breath, and (3) reported a doctors' diagnosis of asthma or allergy. Those fulfilling this definition were further subdivided according to the serum IgE concentration. This definition is based on an earlier work by the authors. 3 The use of augmentation therapy use refers to the IV infusion of purified AAT at a weekly dose of 60 mg/kg. The decision to use this therapy, the dose, and schedule was determined by the subjects' personal physician. For the purposes of this study, subjects were classified as having ever or never received augmentation therapy during the study.
Analysis of Data
Categorical data were summarized as frequencies and percentages, and quantitative data were summarized by the mean and either SD or SE. Serum IgE concentrations in international units per milliliter from 61% of the participants were reported as Ͻ 33.1. IgE concentrations were grouped as high (Ն 100 IU/mL) and low (Ͻ 100 IU/mL). 11 Comparisons of the IgE groups were performed by 2 tests for categorical data. Spearman rank correlation coefficients described the association between the ordinal IgE categories and continuous variables. Reported p values are considered statistically significant if Յ 0.05.
As previously described, 8 the FEV 1 slope for individuals was calculated for those with two or more postbronchodilator measurements obtained Ն 1 year apart. Using a linear mixed-effects model, 12 a least-squares regression of FEV 1 vs time since enrollment was calculated. Analysis of variance was used to analyze the mean FEV 1 decline with respect to the interaction between asthma and an elevated IgE, and between asthma and augmentation therapy for all subjects. These analyses were also performed with adjustments for gender, smoking status, age, and bronchodilator response. Least-squares means were computed to provide estimates of mean FEV 1 decline for subgroups of patients.
Results

Prevalence of Asthma Features in the Cohort
This report is based on 1,052 of 1,129 participants (93%) who completed questionnaires, spirometry, and for whom IgE data were available. Of this cohort, 56% are of male gender, with a mean Ϯ SD age of 46 Ϯ 11 years and mean FEV 1 of 47 Ϯ 30% predicted. The mean serum AAT level for the cohort is 5.8 Ϯ 1.4 mol/L.
Of the 1,052 participants, 82% reported wheezing without a cold, almost 90% of subjects reported wheezing with a cold, and 66% reported more than one wheezing attack with shortness of breath ( Table 1) . Of those with wheezing attacks, 62% required medication. The mean Ϯ SD age of onset of the first attack was 31 Ϯ 16 years. Self-reported respiratory allergy and asthma diagnosed by a doctor occurred in 29% and 38%, respectively.
A significant bronchodilator response occurred in 28% of individuals during the first visit and in 49% over all visits (mean number of visits, 5.0 Ϯ 2.5). In those with a significant bronchodilator response, the mean value of the maximum FEV 1 increase over all visits was 382 Ϯ 180 mL (median, 330 mL; range, 202 to 1,492 mL). Based on the percentage of predicted, the mean increase was 37.6 Ϯ 23.1% (median, 33.3%; range, 12 to 316%).
Asthma Features in the Cohort
The percentage of subjects showing asthma features at any visit according to the presence of significant airflow obstruction is shown in Table 2 . Clinical features of asthma are present in 21% overall, in 23% (197 of 857 patients) with significant airflow obstruction (FEV 1 Ͻ 80%) and in 12.5% (23 of 184 patients) with an FEV 1 of Ն 80%. A much smaller proportion of the cohort with asthma have an elevated IgE, approximately 5% in the group with airflow obstruction (43 of 857 patients) and 7% in the group without (13 of 184 patients). As expected, the mean maximum improvement in FEV 1 after bronchodilator is greater in the groups with asthma compared to the groups without (372 Ϯ 189 mL vs 214 Ϯ 156 mL, p Ͻ 0.001; and 459 Ϯ 221 mL vs 228 Ϯ 226 mL, p Ͻ 0.001, for the groups with normal and elevated IgE levels, respectively).
Relationship of Elevated Serum IgE Level to Asthma-Associated Symptoms and Signs
The relationship of key variables to the presence or absence of an elevated IgE level was determined (Table 3 ). An IgE level Ն 100 IU/mL, present in 176 of the cohort (16.7%), is significantly more common in male subjects and significantly associated with some wheezing variables or a history of asthma or allergy. An elevated IgE level (Ն 100 IU/mL) is neither associated with a smoking history nor with attacks of shortness of breath.
There is a slight but significant correlation between maximum FEV 1 bronchodilator response for all visits and the IgE level (r ϭ 0.12, p Ͻ 0.001). This relationship is not observed when FEV 1 is expressed as the percentage of predicted.
Maximum FEV 1 in the Groups Showing Asthma Features
A comparison of the maximum postbronchodilator FEV 1 (percentage of predicted Ϯ SE) at any visit was made according to the presence of asthma and an elevated IgE level. In the presence of a normal IgE level, the group with asthma has a significantly lower FEV 1 percentage of predicted than the group without clinical asthma (41 Ϯ 1.6% vs 48 Ϯ 1.3%, analysis of variance p ϭ 0.005). In the presence of an elevated IgE level, there is no significant difference in FEV 1 percentage of predicted in the group with clinical features of asthma compared to the group without (51 Ϯ 4.5% vs 48 Ϯ 1.3%, p ϭ 0.1). 
Rate of FEV 1 Decline in the Groups Showing Asthma Features
Median follow-up for the cohort was 52 months (range, 12 to 86 months). Table 4 shows statistically significant differences in mean rates of FEV 1 decline by gender, smoking status, age, and bronchodilator response, as well as the presence of asthma features. The presence of significant airflow obstruction just fails to reach significance as a predictor of FEV 1 decline in this model (p ϭ 0.06).
The mean rate of decline in FEV 1 is lower for the group without asthma features or an elevated IgE level. The difference is significant when this group was compared to the group with asthma (Ϫ 70 mL/yr vs Ϫ 48.5 mL/yr, p ϭ 0.004). Interestingly, the group without asthma but an elevated IgE level also shows a significantly higher rate of FEV 1 decline when compared with the normal IgE level noasthma group (Ϫ 74.9 vs Ϫ 48.5 mL/yr, p ϭ 0.005).
Multivariable Analysis of FEV 1 Decline According to the Presence of Asthma Features and Airflow Obstruction
Gender, smoking status, age, and bronchodilator response are included as covariables in a multivariable model to describe the relationships between asthma and airflow obstruction on the mean rate of FEV 1 decline (Table 5) . After adjusting for these covariables, age, smoking status, and bronchodilator response are significant independent predictors for FEV 1 decline in this model (p Ͻ 0.001). The most rapid decline in FEV 1 occurs in the age group (30 to 44 years) that coincides with the mean age of onset of self-reported wheezing (31 Ϯ 16 years). Asthma as defined is not a significant predictor (p ϭ 0.09).
Effect of Augmentation Therapy on FEV 1 Decline According to the Presence of Asthma Features
By extending the multivariable model to include the use of augmentation therapy, the effect of augmentation therapy on FEV 1 decline according to the presence or absence of asthma was determined. There is no significant difference in either the number of follow-up visits (mean range, 4.8 to 6.4 visits; median range, 5 to 6 visits) or the follow-up time (mean range, 47 to 60 months; median range, 48 to 60 months) between those ever and never receiving augmentation therapy for each group. The percentage of subjects receiving augmentation therapy ranges from 67 to 82% for the asthma/IgE groups defined in Tables 4, 5. Smoking status, age, and bronchodilator response remain significant predictors of FEV 1 decline. In the group with asthma and an elevated IgE level (n ϭ 36), FEV 1 decline is significantly less in those not receiving augmentation compared to the group receiving this therapy (n ϭ 18) [p ϭ 0.043]. There was no effect of augmentation therapy on FEV 1 decline in the other groups when compared by asthma features.
The mean baseline FEV 1 percentage of predicted for the subgroups not receiving augmentation therapy was significantly greater than for those receiving 
Discussion
This study describes the features of asthma in a large cohort of subjects with severe AAT deficiency. It shows that a high proportion of subjects report wheezing symptoms and show a bronchodilator response. Wheezing is reported in Ͼ 80% at baseline and almost universally during a respiratory infection. Nearly 70% of participants report attacks of wheezing with shortness of breath. This study also shows that the first attack of wheezing was self-reported to occur at a mean age of 31 years, a decade and a half before the mean age of presentation to the AAT registry. It is unknown whether this symptom results from early development of emphysema, an asthmatic condition, or both. It is possible that a condition diagnosed by physicians as asthma develops as an early manifestation in those destined to acquire emphysema.
A purpose of this study is to determine if asthma is associated with AAT deficiency. The diagnosis of asthma in any group with COPD is difficult because wheezing and reversible airflow obstruction are common manifestations of both conditions. For example, the Intermittent Positive Pressure Breathing trial 5 of 985 subjects reported a mean wheezing score of approximately 2, meaning occasionally with exercise and an average bronchodilator response of 15% baseline. The Lung Health Study, 13 which enrolled subjects with mild airflow obstruction (mean FEV 1 , 75.1 Ϯ 8.8%), reported a bronchodilator response of Ն 10% baseline in 10.9% of participants and physician-confirmed asthma from 6.8 to 7.6%. In the Tucson study, Sherrill et al 14 
Wheezing in chronic airflow obstruction is likely to result in part from a reduction of airway diameter due to loss of elastic recoil. Indeed, bronchodilator response as a percent of FEV 1 becomes more common the lower the baseline FEV 1 . 5 In the current study, a bronchodilator response occurred in nearly half of subjects and in 12.5% of those with a normal FEV 1 (n ϭ 184). This percentage is greater than has been reported in general population studies. In 2,609 healthy subjects, Dales et al 15 reported that the 95th percentile of bronchodilator response was 9% and occurred in approximately 3% of those with a normal FEV 1 . Lorber et al 16 reported 10% of a cohort of 1,063 subjects exceeded a change in FEV 1 of 7.7% after bronchodilator. However, of this group, 65 subjects were asthmatics. The increased percentage of subjects with a normal FEV 1 showing a response to bronchodilator suggests that bronchial hyperresponsiveness and asthma may occur at an early stage of the natural history of lung disease in AAT deficiency.
Previous studies indicate that clinical features of asthma are present in a proportion of those with severe AAT deficiency. A diagnosis of asthma was considered present in 11% of 166 patients with PI * Z AAT deficiency participating in a British Thoracic Society survey. 4 More recently, Piitulainen et al 17 reported a mean bronchodilator response of 400 mL (6%) in 41% of a group of 225 never-smoking subjects with severe AAT deficiency. The mean FEV 1 for the cohort was 2.4 L (84% predicted), with only 13 of the group showing a postbronchodilator rise in FEV 1 Ͼ 15%. In another case series of 52 subjects with AAT deficiency, self-reported asthma was present in 25% of those with an FEV 1 Ͻ 65% predicted. 18 Wheezing was present in 60% of this group. In the current study, using a definition similar to that previously reported, 3 asthma was present in 21% of this large cohort.
Eden et al 3 used total serum IgE level and atopy to refine the definition of asthma in a group with severe AAT deficiency. Although the number of subjects was small in this study, asthma associated with atopy was more common in subjects with emphysema and severe AAT deficiency than in those with COPD without the deficiency. In the current study total serum IgE level was used as a surrogate marker for atopy that is known to be associated with bronchial hyperresponsiveness. 11, 19 An elevated total serum IgE level (Ն 100 IU/mL) is found in nearly 17% of this cohort and is more common in men, in those with self-reported allergy and asthma, a history of wheezing, and in subjects showing a bronchodilator response. There is also a weak but statistically significant correlation between total IgE and absolute maximum FEV 1 bronchodilator response. Thus, an elevated IgE is a marker for a history of atopy, and defines in our cohort a group more susceptible to allergen-induced asthma. An elevated serum IgE has been reported to be associated with an increased FEV 1 decline in COPD. 14, 20 In this study, there is evidence to support this, as univariable analysis shows FEV 1 decline to be greater in the group without asthma and an elevated IgE compared to the group with a normal IgE. However, mean FEV 1 percentage of predicted is significantly lower in the group with asthma features and a normal IgE level compared to the group with asthma and an elevated IgE level. Also, the groups are unmatched for age, smoking status, and other variables. Furthermore, the findings do not take into account the interaction of IgE with age, smoking status, bronchodilator response, and asthma on FEV 1 decline.
There is a greater decline in FEV 1 in those with asthma features (Ն 64 mL/yr) than the mean rate of decline previously reported for this cohort (Ϫ 54 mL/yr), 8 but less than the mean FEV 1 decline reported for a smaller Danish study. 21 In a multivariable model (Table 5) , age, smoking status, and bronchodilator response are significant determinants of FEV 1 decline but not other features of asthma such as wheezing attacks and an elevated IgE level. Although the observational design of this study creates the possibility of bias, the findings indicate that young individuals with AAT deficiency who smoke and show significant reversibility of airflow obstruction have the highest rate of FEV 1 decline. The most rapid FEV 1 decline occurs at the same age range (30 to 44 years) that subjects report onset of wheezing (mean age, 31 Ϯ 16 years). Therefore, in those who acquire irreversible airflow obstruction, a period of significant bronchial hyperresponsiveness and accelerated loss of lung function may occur early in the natural history. In support of this observation, a report from the Copenhagen Heart Study 22 shows that accelerated loss of FEV 1 occurs in subjects with new-onset asthma. The period of most rapid lung function decline may be missed in those with AAT deficiency newly diagnosed with clinical asthma.
Pretreatment with AAT has been shown to block the development of airway hyperresponsiveness in a model of sheep allergy. 23 Therefore, increasing the local concentration of AAT by augmentation therapy might ameliorate inflammation, reduce bronchial hyperresponsiveness, and prevent the development of chronic airway changes. Accordingly, the groups were divided according to whether augmentation therapy was ever received or not. Overall, multivariable analysis did not show that augmentation therapy is more effective in reducing FEV 1 decline in the groups with asthma compared to the group without. The apparent lack of effectiveness of augmentation for the groups overall is consistent with the findings of the NHLBI registry. 8 In the registry, subgroup analysis showed augmentation to be most effective in the FEV 1 35 to 49% category. The definition of asthma in this study is based on simple clinical criteria and lacked any objective measurement of bronchial hyperresponsiveness or airway inflammation that may be important in determining loss of lung function in both asthma and COPD. 24, 25 Significantly, the more severely affected subjects with a lower FEV 1 were more likely receive augmentation therapy, leading to selection for treatment of those who may have been more susceptible to loss of lung function. This may have limited the power of the analysis to detect a benefit of augmentation therapy in asthma.
In conclusion, features of asthma are common in those with severe AAT deficiency and symptoms may occur early in the course of the development of airflow obstruction. In a small percentage of this cohort, an elevated IgE is associated with a history of allergy and wheezing and is an indicator of atopy. This analysis also shows that an elevated total IgE level is associated with an increased rate of FEV 1 decline but is not an independent risk factor. However, reversible airflow obstruction is common and is an important factor in the accelerated FEV 1 decline seen in young current smokers with AAT deficiency. Asthma as defined in this study is not an independent risk factor for loss of lung function once bronchodilator response, age, and smoking status are considered. In this analysis, augmentation therapy is not more effective in preventing the loss of lung function in those with asthma compared to those without.
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